[Experience with therapy of prostate cancer in the Primorye Territory].

The paper deals with a clinical evaluation of the results and side-effects of hormonotherapy of 108 patients with prostatic cancer, aged 46-96. Among the most frequent side-effects were: gynecomastia, sexual and neurologic dysfunction. Ziproterone acetate was followed by less frequent side-effects than generic flutamide. Monotherapy was tolerated better than maximum androgen deprivation. No significant correlation was found between survival, lethality and serologic progression duration, on the one hand, and variety of antiandrogen or androgen deprivation technique, on the other.